Abstract

The present invention refers to parenterally administered pharmaceutical compositions comprising non-steroidal anti-inflammatory drugs or salts thereof, reconstitutable with specific reconstitution solution and free of buffering agent.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/08 - Solutions
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

N-acylhydrazone compounds that are Nav 1.7 and/or Nav 1.8 inhibitors, including N-acylhydrazone compounds of Formula (I), wherein the substituents R1 to R6 are independently selected from the groups defined in the specification, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits, and which are applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders. N-acylhydrazone compounds that are Nav 1.7 and/or Nav 1.8 inhibitors, including N-acylhydrazone compounds of Formula (I), wherein the substituents R1 to R6 are independently selected from the groups defined in the specification, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits, and which are applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07D 241/32 - (Amino-pyrazinoyl) guanidines

Abstract

The invention relates to Nav1.7- and/or Nav1.8-inhibiting phenolic compounds. More specifically, the present invention relates to phenolic compounds of formula (I): (I), in which the substituents R1 to R12 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/38 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/16 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07C 15/12 - Polycyclic non-condensed hydrocarbons
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to Nav1.7- and/or Nav1.8-inhibiting amides. More specifically, the present invention relates to amides comprising formula (I): (Ia) (Ib), in which the substituents R1 to R27 are selected independently of the groups defined in the description, as well as to processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07C 15/12 - Polycyclic non-condensed hydrocarbons
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/609 - Amides, e.g. salicylamide
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to Nav1.7- and/or Nav1.8-inhibiting hydrazides. More specifically, the present invention relates to hydrazides comprising formula (I):(I), in which the substituents R1 to R8 are selected independently of the groups defined in the description, as well as to processes for preparing same, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/38 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/14 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to Nav1.7- and/or Nav1.8-inhibiting aryl pyridine compounds. More specifically, the present invention relates to aryl pyridines comprising formula (I): (I), in which the substituents R1 to R10 are selected independently of the groups defined in the description, as well as to processes for preparing same, compositions comprising at least one of these compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related diseases.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/38 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/16 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to Nav1.7- and/or Nav1.8-inhibiting hydroxamates. More specifically, the present invention relates to hydroxamates that comprise formula (I): (I), in which the substituents R1 to R10, as well as the derivatives thereof, R11 to R20, are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07C 15/12 - Polycyclic non-condensed hydrocarbons
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/609 - Amides, e.g. salicylamide
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to an immunoglobulin-preserving method for producing lyophilised powdered human milk and to the kit for reconstituting the easily fractionated lyophilised material.

IPC Classes  ?

• A23C 1/08 - Freeze drying
• A23C 9/18 - Milk in dried and compressed or semi-solid form
• A23C 9/16 - Agglomerating or granulating milk powderMaking instant milk powderProducts obtained thereby
• A61K 35/20 - MilkWheyColostrum
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The present invention relates to a pharmaceutical composition comprising the association of desloratadine and a hydrotropic agent, a method for producing same and the uses thereof.

IPC Classes  ?

• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4465 - Non-condensed piperidines, e.g. piperocaine only substituted in position 4
• A61K 9/10 - DispersionsEmulsions
• A61K 9/08 - Solutions
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 27/14 - Decongestants or antiallergics
• A61P 37/08 - Antiallergic agents
• A61K 9/0053 -
• A61K 9/0056 -

Abstract

The present invention relates to a bioadhesive nasal spray composition comprising granisetron hydrochloride, resulting in a bioadhesive system for systemic delivery, as well as to the production method thereof and to the use thereof to manufacture a medicament in the form of a bioadhesive nasal spray.

IPC Classes  ?

• A61K 47/38 - CelluloseDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics

Abstract

The present invention relates to a vilazodone docusate salt, a process for producing same, a pharmaceutical composition containing the vilazodone docusate salt and the use thereof.

IPC Classes  ?

• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 25/24 - Antidepressants

Abstract

The present invention relates to a novel anhydrous crystalline form, called the anhydrous crystalline T form, of the Active Pharmaceutical Ingredient (API) naloxone hydrochloride and to a process for producing same.

IPC Classes  ?

• C07D 489/08 - Oxygen atom

Abstract

The present invention relates to the crystalline form of phentermine hydrochloride monohydrate and processes for obtaining said crystalline form. Phentermine or 2-methyl-1-phenylpropan-2-amine is found in the hydrochloride salt form, being a central nervous system stimulant, used as an appetite suppressant and stimulant in medicaments. The present invention belongs to the fields of chemistry and pharmacy.

IPC Classes  ?

• C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
• C07C 209/86 - Separation

Goods & Services

Sale service for medicines for human health.

Abstract

N-N-N-acylhydrazone compounds of formula (I), and to the methods for producing same, compositions, kits, uses and methods for treating or preventiing depressive disorders, anxiety disorders, rheumatoid arthritis and/or neuropathic pain.

IPC Classes  ?

• C07C 251/86 - Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
• C07D 213/88 - Nicotinoylhydrazones
• C07D 237/10 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 241/14 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 251/12 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
• C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 257/08 - Six-membered rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

Goods & Services

(1) Sale service for medicines for human health.

Abstract

The invention relates to N-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention relates to N-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/42 - Oxazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/425 - Thiazoles
• A61K 31/433 - Thiadiazoles
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to N-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/4245 - Oxadiazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/433 - Thiadiazoles
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07D 213/86 - HydrazidesThio or imino analogues thereof
• C07D 213/87 - HydrazidesThio or imino analogues thereof in position 3
• C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 285/08 - 1,2,4-ThiadiazolesHydrogenated 1,2,4-thiadiazoles
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

NN-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/4965 - Non-condensed pyrazines
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Goods & Services

Pharmaceutical preparations for treatment of inflammatory diseases

Abstract

The foaming topical pharmaceutical composition is a topical pharmaceutical composition providing a pleasant sensation that inhibits the formation of crystals of the active substance, and the use thereof to treat alopecia and other related disorders.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61Q 7/00 - Preparations for affecting hair growth
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

The present invention refers to parenterally administered pharmaceutical compositions comprising non-steroidal anti-inflammatory drugs or salts thereof, reconstitutable with specific reconstitution solution and free of buffering agent.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/08 - Solutions

Abstract

The present invention relates to a crystalline form of phentermine hydrochloride monohydrate and processes for obtaining said crystalline form. Phentermine or 2-methyl-1-phenylpropan-2-amine is found in the form of a hydrochloride salt, and is a central nervous system stimulant, being used as an appetite suppressant and stimulant in medicines. The present invention pertains to the fields of chemistry and pharmacy.

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine
• C07C 209/84 - Purification
• C07C 209/90 - StabilisationUse of additives
• C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains

Abstract

The present invention relates to a crystalline form of phentermine hydrochloride monohydrate and processes for obtaining said crystalline form. Phentermine or 2-methyl-1-phenylpropan-2-amine is found in the form of a hydrochloride salt, and is a central nervous system stimulant, being used as an appetite suppressant and stimulant in medicines. The present invention pertains to the fields of chemistry and pharmacy.

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine

Goods & Services

Fertilizers; chemicals for use in industry, science as well as in agriculture. Medicines for veterinary purposes.

Abstract

The present invention relates to parenterally administered pharmaceutical compositions comprising non-steroidal anti-inflammatories or salts thereof, which can be reconstituted with specific reconstitution solution that is free of buffering agent.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/42 - Oxazoles
• A61K 9/08 - Solutions
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to parenterally administered pharmaceutical compositions comprising non-steroidal anti-inflammatories or salts thereof, which can be reconstituted with specific reconstitution solution that is free of buffering agent.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/42 - Oxazoles
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Goods & Services

Medicinal preparations for treating diseases of the nervous system, central nervous system, and diabetes for use in human medicine Providing commercial information in the field pharmaceuticals for treating diseases of the nervous system and central nervous system for humans

Abstract

The present invention relates, in general, to a veterinary product for intramammary infusion, comprising antibiotics and anti-inflammatories in association with pharmaceutically acceptable excipients, which provides effective treatment for mastitis in milk‑producing herds.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/04 - Antibacterial agents

Abstract

In general, the present invention relates to veterinary compositions that can be used for treating parasitic diseases in animals, particularly dairy cattle, comprising avermectins and specific excipients acceptable for veterinary purposes. The present invention also relates to uses of said compositions, kits and improved method for treating parasitic diseases in animals.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 9/08 - Solutions
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• A61P 33/10 - Anthelmintics
• A61P 33/00 - Antiparasitic agents

Abstract

The present invention relates, as a whole, to an electrolyte formulation that can be used in the treatment of kidney failure, in particular in continuous veno-venous hemodialysis (CVVHD), and can take various configurations, offering benefits in the treatment of critical patients. Specifically, the present invention provides a safer treatment, reducing the incidence of unwanted effects, such as metabolic acidosis. The invention also relates to a kit containing the electrolyte formulation, as well as methods for optimizing hemodialysis treatment.

IPC Classes  ?

• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides
• A61J 1/10 - Bag-type containers
• A61P 7/08 - Plasma substitutesPerfusion solutionsDialytics or haemodialyticsDrugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
• A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis

Abstract

The present invention relates to an oral pharmaceutical composition containing at least one stomach acid suppressant, particularly a proton pump inhibitor (PPI), and a prokinetic agent (PA), designed to treat disorders related to excess stomach acid, for example gastro-oesophageal reflux disease.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/20 - Pills, lozenges or tablets
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

In general, the present invention relates to oral pharmaceutical compositions comprising at least one muscle relaxant and at least one non-steroidal anti-inflammatory drug, in combination with pharmaceutically acceptable excipients, said pharmaceutical compositions having an analgesic and anti-inflammatory effect, for example in the treatment of skeletal muscle dysfunction and other related dysfunctions. A further aspect of the invention relates to the use of said compositions for manufacturing drugs that can be used for treating skeletal muscle dysfunction and other related dysfunctions.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/433 - Thiadiazoles
• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a composition that is of use in the treatment of benign prostatic hyperplasia 5. More specifically, the present invention relates to a composition comprising finasteride and doxazosin mesylate, which can be used for treating benign prostatic hyperplasia.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate